Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
178
Shown on this page
12
Current sort
Recently updated
Therapy scope
Tirzepatide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 13–24 of 178 matching trials for Tirzepatide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099
View directory record Official record
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
15,374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
165
States / cities
Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
49
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Recruiting Phase 3 Interventional

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086
View directory record Official record
Conditions
Ulcerative Colitis, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Active, not recruiting No phase listed Observational

Study of Patients Being Treated With Anti-obesity Medication

NCT06790160
View directory record Official record
Conditions
Obesity and Overweight
Interventions
Not listed
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Not yet recruiting Phase 4 Interventional

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

NCT07832084
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators
Interventions
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
Drug · Behavioral
Lead sponsor
Jing Luo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Not yet recruiting Phase 3 Interventional

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT07855900
View directory record Official record
Conditions
Obesity
Interventions
Survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Riverview, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Recruiting Early Phase 1 Interventional

Tirzepatide in Obesity-Driven Endometrial Cancer

NCT07065552
View directory record Official record
Conditions
Endometrial Cancer, Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Active, not recruiting Phase 4 Interventional

GLP-1s to Enhance Lasting Optimal Weight

NCT06861439
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Active, not recruiting Phase 4 Interventional

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

NCT06854614
View directory record Official record
Conditions
Obesity
Interventions
Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®)
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT06603571
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3841136, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 10:19 AM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.